108 related articles for article (PubMed ID: 845874)
21. Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
Glennon RA; Young R; Benington F; Morin RD
J Med Chem; 1982 Oct; 25(10):1163-8. PubMed ID: 7143352
[TBL] [Abstract][Full Text] [Related]
22. Regiochemistry and substrate stereoselectivity of O-demethylation of verapamil in the presence of the microsomal fraction from rat and human liver.
Nelson WL; Olsen LD; Beitner DB; Pallow RJ
Drug Metab Dispos; 1988; 16(2):184-8. PubMed ID: 2898330
[TBL] [Abstract][Full Text] [Related]
23. Metabolic study of 2,5-dimethoxy-4-ethylamphetamine (DOET) in rats.
Tansey LW; Estevez VS; Ho BT
Proc West Pharmacol Soc; 1975; 18():362. PubMed ID: 1182040
[No Abstract] [Full Text] [Related]
24. Isomeric cyclopropyl ring-methylated homologues of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine, an hallucinogen analogue.
Jacob JN; Nichols DE
J Med Chem; 1982 May; 25(5):526-30. PubMed ID: 7086838
[TBL] [Abstract][Full Text] [Related]
25. Electrochemical study of the hallucinogen (+-)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminopropane.
Richter P; Morales A; Gómez-Jeria JS; Morales-Lagos D
Analyst; 1988 Jun; 113(6):859-63. PubMed ID: 3218759
[No Abstract] [Full Text] [Related]
26. Different developmental profiles for the hepatic N-demethylation of N-methylamphetamine and N,N-dimethylamphetamine in the rat.
Henderson PT
Gen Pharmacol; 1978; 9(1):59-63. PubMed ID: 640373
[No Abstract] [Full Text] [Related]
27. Effect of 2,5-dimethoxy-4-methylamphetamine (DOM, STP) on the uptake and release of 14C-5-hydroxytryptamine by rabbit blood platelets.
Huang JT; Airaksinen MM; Ho BT
Eur J Pharmacol; 1974 Feb; 25(2):251-4. PubMed ID: 4435028
[No Abstract] [Full Text] [Related]
28. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
Sanders-Bush E; Burris KD; Knoth K
J Pharmacol Exp Ther; 1988 Sep; 246(3):924-8. PubMed ID: 2843634
[TBL] [Abstract][Full Text] [Related]
29. Stereospecific actions of 2,5-dimethoxy-4-methylamphetamine (DOM) on colonic temperature in the rat at various ambient temperatures.
Beaton JM; Benington F; Bradley RJ; Kuhlemeier KV; Morin RD
Br J Pharmacol; 1976 Aug; 57(4):547-50. PubMed ID: 134754
[TBL] [Abstract][Full Text] [Related]
30. Discriminative stimulus properties of MDA analogs.
Glennon RA; Young R; Rosecrans JA; Anderson GM
Biol Psychiatry; 1982 Jul; 17(7):807-14. PubMed ID: 6126227
[TBL] [Abstract][Full Text] [Related]
31. Application of chemical ionization mass spectrometry to the study of stereoselective in vitro metabolism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane.
Weinkam RJ; Gal J; Callery P; Castagnoli N
Anal Chem; 1976 Jan; 48(1):203-9. PubMed ID: 1244761
[No Abstract] [Full Text] [Related]
32. Metabolism and pharmacokinetics of metaclazepam (Talis), Part III: Determination of the chemical structure of metabolites in dogs, rabbits and men.
Borchers F; Achtert G; Hausleiter HJ; Zeugner H
Eur J Drug Metab Pharmacokinet; 1984; 9(4):325-46. PubMed ID: 6532806
[TBL] [Abstract][Full Text] [Related]
33. Identification of a nitrone as an in vitro metabolite of N-methylamphetamine.
Coutts RT; Jones GR; Liu SF
Biomed Mass Spectrom; 1978 Jun; 5(6):418-22. PubMed ID: 678611
[TBL] [Abstract][Full Text] [Related]
34. Metabolic O-demethylation of 3,4-dimethoxyamphetamine in vivo in dog and monkey.
Midha KK; Bailey K; Cooper JK; Hubbard JW
Xenobiotica; 1979 Aug; 9(8):485-90. PubMed ID: 117645
[TBL] [Abstract][Full Text] [Related]
35. Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist.
Ismaiel AM; De Los Angeles J; Teitler M; Ingher S; Glennon RA
J Med Chem; 1993 Aug; 36(17):2519-25. PubMed ID: 8355253
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the effects of R-(-)-2-amino-1-(2,5-dimethoxy-4-methylphenyl) propane (DOM), r-(-)-2-amino-1-(2,5-dimethoxy-4-methylphenyl) butane (BL-3912A) and 5-hydroxytryptamine on non-innervated vascular smooth muscle.
Dyer DC
Res Commun Chem Pathol Pharmacol; 1976 Jul; 14(3):449-54. PubMed ID: 959651
[TBL] [Abstract][Full Text] [Related]
37. The stereoselective metabolism of ethylamphetamine with fortified rabbit liver homogenates.
Beckett AH; Haya K
Xenobiotica; 1978 Feb; 8(2):85-96. PubMed ID: 626007
[TBL] [Abstract][Full Text] [Related]
38. DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines.
Glennon RA; Young R; Jacyno JM; Slusher M; Rosecrans JA
Eur J Pharmacol; 1983 Jan; 86(3-4):453-9. PubMed ID: 6572591
[TBL] [Abstract][Full Text] [Related]
39. Designer drugs 2,5-dimethoxy-4-bromo-amphetamine (DOB) and 2,5-dimethoxy-4-bromo-methamphetamine (MDOB): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques.
Ewald AH; Fritschi G; Bork WR; Maurer HH
J Mass Spectrom; 2006 Apr; 41(4):487-98. PubMed ID: 16470568
[TBL] [Abstract][Full Text] [Related]
40. Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human.
Carmo H; Hengstler JG; de Boer D; Ringel M; Remião F; Carvalho F; Fernandes E; dos Reys LA; Oesch F; de Lourdes Bastos M
Toxicology; 2005 Jan; 206(1):75-89. PubMed ID: 15590110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
